Analysis of CA-MRSA Transmission: An ED Population Sampling Strategy
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details. |
ClinicalTrials.gov Identifier: NCT02363166 |
Recruitment Status :
Recruiting
First Posted : February 13, 2015
Last Update Posted : June 13, 2023
|
- Study Details
- Tabular View
- No Results Posted
- Disclaimer
- How to Read a Study Record
Condition or disease | Intervention/treatment |
---|---|
Methicillin-Resistant Staphylococcus Aureus | Other: Acute Abscess Group |
Prospective cross-sectional study involving 500 patients enrolled over a one year period at the UFHealth Shands Hospital's Adult and Pediatric Emergency Department. The collected information will serve as pilot data for a future large comprehensive multi-site study.
Patients will have a wound culture and a nasal swab obtained as part of the study, which will be assessed for MRSA isolates using next-generation whole genome sequencing. The principal investigator or PI designee will also survey participants and review hospital records.
Study Type : | Observational |
Estimated Enrollment : | 575 participants |
Observational Model: | Case-Only |
Time Perspective: | Cross-Sectional |
Official Title: | Molecular Epidemiology and Phylodynamic and Phylogeographic Analysis of Community-associated Methicillin-resistant Staphylococcus Aureus (CA-MRSA) Transmission: An Emergency Department Population Sampling Strategy |
Actual Study Start Date : | August 2015 |
Estimated Primary Completion Date : | February 5, 2025 |
Estimated Study Completion Date : | February 5, 2025 |
Group/Cohort | Intervention/treatment |
---|---|
Acute Abscess Group
Adults and pediatric patients presenting to the UFHealth Shands Emergency Department with evidence of an acute abscess, or skin/soft tissue infection, which can be sampled for culture and sensitivity testing will be recruited.
|
Other: Acute Abscess Group
Samples collected for culture and sensitivity testing depending on acute abscess, or skin/soft tissue infection. |
- Strain Relatedness Identification Through Phylogenetic Analysis [ Time Frame: 1 Hour ]Molecular (spa-typing) and genomic (WGS) relatedness of MRSA strains in isolates in ED populations presenting with SSTIs.
- Strain Transmission Through Analysis of Genetic Clustering [ Time Frame: 1 year ]Phlyodynamic analysis of MRSA transmission course by strain
- Patient Level Characteristics of Skin and Soft Tissue Infection (SSTI) Presentation [ Time Frame: 6 Months ]To determine patient-level characteristics, including social and medical history, associated with a presentation related to SSTIs.
- Pediatric and Adult Population Presentation Characteristics in Skin and Soft Tissue Infection (SSTI) [ Time Frame: 6 Months ]Compare patient-level characteristics and phylogenetic clustering between pediatric and adult patients presenting with SSTIs.
Biospecimen Retention: Samples With DNA
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.
Ages Eligible for Study: | 1 Month and older (Child, Adult, Older Adult) |
Sexes Eligible for Study: | All |
Accepts Healthy Volunteers: | No |
Sampling Method: | Non-Probability Sample |
Inclusion Criteria:
- Patient or Legally Authorized Representative (LAR) must have voluntarily signed an Institutional Review Board-approved informed consent form before initiation of any study procedures
- Patient presents with an acute abscess or a non-post-operative skin/soft tissue infection
- Patient presents through the UFHealth Shands Emergency Department
Exclusion Criteria:
- Patients who are employed by UFHealth and provide direct patient care
- Patients who have previously been enrolled in the study
- Patients who are not suitable for the study in the opinion of the investigator
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT02363166
Contact: Joseph A Tyndall, MD | 352-265-5911 | tyndall@ufl.edu | |
Contact: Scott Cohen | 954-326-4202 | scohen211@phhp.ufl.edu |
United States, Florida | |
UF Health | Recruiting |
Gainesville, Florida, United States, 32608 | |
Contact: Joseph A Tyndall, MD 352-265-5911 tyndall@ufl.edu | |
Contact: Scott Cohen 954-326-4202 scohen211@phhp.ufl.edu | |
Principal Investigator: Joseph A Tyndall, MD |
Principal Investigator: | Joseph A Tyndall, MD | University of Florida |
Responsible Party: | University of Florida |
ClinicalTrials.gov Identifier: | NCT02363166 |
Other Study ID Numbers: |
IRB201400426 |
First Posted: | February 13, 2015 Key Record Dates |
Last Update Posted: | June 13, 2023 |
Last Verified: | June 2023 |
Studies a U.S. FDA-regulated Drug Product: | No |
Studies a U.S. FDA-regulated Device Product: | No |
Staphylococcal Infections Gram-Positive Bacterial Infections Bacterial Infections Bacterial Infections and Mycoses Infections |